Close to a billion dollars and upwards of a decade of scientific investment are minimal requirements for the launch of a clinically efficacious drug. With the stakes so high, it is incumbent on drug/biologic manufacturers to aggressively pursue commercial success as defined by:
- A strong return on investment, sustained over time
- Access to the drug by the broadest range of eligible patients
- Market-sensitized pricing and reimbursement that supports uptake and treatment persistence
HERON is an evidence-based life sciences consultancy that provides commercial decision support throughout the product/portfolio lifecycle. With expertise and methodologies that align evidence development and economic evaluation with pricing, reimbursement, and market access planning, HERON is unique in its ability to realize product value and commercial opportunity at any point in your decision-making process.